Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7233114 | 0.84 | MEN1 (0.43) | MAOBMAPTMEN1KMT2ACA9 | |
| SCHEMBL13742980 | 0.81 | CA12 (0.46) | MAOBMAPTMEN1KMT2AMAOA | |
| SCHEMBL6718661 | 0.80 | AR (0.55) | ARMAOBMAPTMEN1KMT2A | |
| SCHEMBL7233667 | 0.79 | TDP1 (0.52) | ARMAPTMEN1KMT2AESR1 | |
| SCHEMBL10593907 | 0.77 | MAOA (0.66) | ARMAPTMEN1KMT2AESR1 | |
| SCHEMBL12113006 | 0.76 | MAPT (0.71) | MAPTMEN1KMT2ACA9CA12 | |
| SCHEMBL4167668 | 0.76 | AR (0.53) | ARMAOBMAPTMEN1KMT2A | |
| SCHEMBL5332842 | 0.74 | MAPT (0.63) | MAOBMAPTMEN1KMT2AMAOA | |
| SCHEMBL3663573 | 0.74 | MAOA (0.52) | HTTADORA3ADORA2AMAOBMAPT | |
| SCHEMBL11385812 | 0.73 | MAOA (0.63) | ADORA3ADORA2AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021118728-A2 | GLUCOCORTICOID RECEPTOR RADIOLIGANDS AND METHODS FOR THEIR PREPARATION AND USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021118728-A2 | GLUCOCORTICOID RECEPTOR RADIOLIGANDS AND METHODS FOR THEIR PREPARATION AND USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20110275632-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275632-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-6593480-B2 | Obesity, hyperglycemia | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| WO-2002070507-A2 | GLYCORTICOID RECEPTOR ANTAGONISTS FOR TREATMENT OF DIABETES | ABBOTT LABORATORIES (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6329534-B1 | USEFUL FOR THERAPY OF TYPE II DIABETES, OBESITY, HYPERGLYCEMIA, INADEQUATE GLUCOSE CLEARANCE, HYPERINSULINEMIA, HYPERTRIGLYCERIDEMIA, AND HIGH-CIRCULATING GLUCOCORTICOID LEVELS | ABBOTT LABORATORIES | 2001-12-11 | — | — | US | disclosed |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | KARO BIO AB (SE) | 2001-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | NR3C1, GPR119, NR3C2 | HTT 3414/4885AR 219/4885ADORA3 604/4885 |
| US-20110275632-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | NR3C1, NR3C2, NR5A1 | HTT 840/4885AR 303/4885ADORA3 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.